Topic:

Influenza

Latest Headlines

Latest Headlines

UPDATED: Serum Institute and Bharat Biotech race to get swine flu vaccines back on the market

Swine flu is making a comeback in India, and with a vengeance. After destroying their existing stocks due to poor demand and short shelf life, Serum Institute and Bharat Biotech will be racing to get their swine flu vaccines back on the market.

VaxInnate reaps $53M for flu jab trials on BARDA contract extension

The U.S. Department of Health and Human Services apparently likes what it's seen from a 5-year contract with VaxInnate. Its Biomedical Advanced Research and Development Authority (BARDA) has extended the contract's base period with the flu vaccine maker, a move that allows for the use of $53 million.

Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot

Flu vaccine maker Protein Sciences may be abandoning its expansion plans in Connecticut, opting instead to build out its New York-based manufacturing site. But it's not for any of the reasons one might expect.

After rocky flu season, vaccinemakers may want to follow Novartis' lead

Heading into this year's flu season, vaccinemakers were hoping to follow up the top-line success they scored last year with quadrivalent rollouts. But with this year's vaccines registering a paltry 23% effectiveness rate this season thanks to a mutated strain, it might be time to make some changes.

Back from the scrap heap, BioCryst wins OK for IV flu drug

BioCryst Pharmaceuticals won its first-ever FDA approval for a new treatment and subsequently saw its shares slide as analysts yawned over its sales potential.

Sanofi adds another quadrivalent to its quiver with Fluzone Intradermal approval

Last year, Sanofi's fourth-quarter flu vaccine sales soared on the introduction of a quadrivalent contender, surging more than 94%. Now, looking to keep that growth coming, the company is adding another four-strain shot to the mix.

UPDATED: Novartis' Fluad off the hook in Italy following 19 deaths

After last week partially banning Novartis' Fluad, Italian officials now say tests on the flu vaccine show the product is safe.

Could oral vaccines shake up the flu shot market? Vaxart's Ph I says maybe

Flu shots are a driving sales force for more than a couple vaccine players. But could an oral alternative disrupt the flu vaccine market down the line?

Novartis drafts TV celeb Nick Cannon to talk up importance of flu vaccines

To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.

Inovio, MedImmune and Penn unite to fight the flu on DARPA's dime

Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.